文献速递神经免疫

儿童期起病多发性硬化持续残疾风险随时间下降

Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2021-01-01

这项回顾性多中心观察研究基于意大利MS注册库,纳入3198例儿童期起病多发性硬化(POMS)患者,按诊断年代(<1993、1993-1999、2000-2006、2007-2013)比较达到EDSS 4.0和6.0的时间。结果显示,较晚诊断年代达到残疾里程碑的累积风险逐渐降低,可能与更早、更长时间使用疾病修饰治疗(DMT)尤其是高效药物有关。

要点

  • POMS患者达到EDSS 4.0和6.0的中位生存时间分别为31.7年和40.5年。
  • 较晚诊断年代达到EDSS 4.0和6.0的风险逐渐降低,2007-2013年HR分别为0.44和0.30。
  • 较晚诊断年代更多患者接受DMT,尤其是高效药物,且用药更早、时间更长。

核心结论

  • 在POMS患者中,近期诊断年代持续残疾风险降低了50%至70%,可能归因于治疗和管理标准的改善。

研究设计与样本

  • 纳入标准为MS发病年龄小于18岁、2014年1月前诊断、病程至少3年;排除原发性进展型MS、发病后1年EDSS评分至少8、诊断日期不可用及EDSS评估少于2次者。
  • 符合标准的POMS患者共4704例,最终纳入3198例,排除1506例。

主要发现

  • 纳入3198例POMS患者,平均发病年龄15.2岁,女性占69%,中位诊断时间3.2年,首发1年和3年年化复发率分别为1.3和0.6,平均随访21.8(标准差11.7)年。
  • 达到EDSS 4.0和6.0的中位生存时间分别为31.7年和40.5年。
  • 达到EDSS 4.0的累积风险随时间逐渐降低:1993-1999年HR 0.70(95%CI 0.58-0.83),2000-2006年HR 0.48(95%CI 0.38-0.60),2007-2013年HR 0.44(95%CI 0.32-0.59)。
  • 达到EDSS 6.0的累积风险同样逐渐降低:1993-1999年HR 0.72(95%CI 0.57-0.90),2000-2006年HR 0.44(95%CI 0.33-0.60),2007-2013年HR 0.30(95%CI 0.20-0.46)。
  • 较晚诊断年代更多POMS患者接受DMT治疗,尤其是高效药物,且给药更早、疗程更长;人口学特征和起病时临床疾病活动度随时间无显著变化。

临床怎么用

  • 对于POMS患者,早期启用DMT尤其是高效药物可能有助于降低长期持续残疾风险。
  • 临床管理应关注诊断年代所反映的治疗标准变化,积极优化治疗策略。

局限性

  • 本研究为回顾性观察性研究,可能存在残余混杂。
  • 数据来源于意大利MS注册库,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging. OBJECTIVE: To evaluate changes in the prognosis of POMS over time in association with changes in therapeutic and managing standards. DESIGN, SETTING, AND PARTICIPANTS: Retrospective, multicenter, observational study. Data were extracted and collected in May 2019 from the Italian MS Registry, a digital database including more than 59 000 patients. Inclusion criteria were MS onset before age 18 years, diagnosis before January 2014, and disease duration of at least 3 years. Exclusion criteria were primary progressive MS, Expanded Disability Status Scale (EDSS) score of at least 8 one year after onset, unavailability of diagnosis date, and less than 2 EDSS score evaluations. Eligible patients were 4704 patients with POMS. According to these criteria, we enrolled 3198 patients, excluding 1506. EXPOSURES: We compared time to reach disability milestones by epoch of MS diagnosis (<1993, 1993-1999, 2000-2006, and 2007-2013), adjusting for possible confounders linked to EDSS evaluations and clinical disease activity. We then analyzed the difference among the 4 diagnosis epochs regarding demographic characteristics, clinical disease activity at onset, and DMTs management. MAIN OUTCOMES AND MEASURES: Disability milestones were EDSS score 4.0 and 6.0, confirmed in the following clinical evaluation and in the last available visit. RESULTS: We enrolled 3198 patients with POMS (mean age at onset, 15.2 years; 69% female; median time to diagnosis, 3.2 years; annualized relapse rate in first 1 and 3 years, 1.3 and 0.6, respectively), with a mean (SD) follow-up of 21.8 (11.7) years. Median survival times to reach EDSS score of 4.0 and 6.0 were 31.7 and 40.5 years. The cumulative risk of reaching disability milestones gradually decreased over time, both for EDSS score of 4.0 (hazard ratio [HR], 0.70; 95% CI, 0.58-0.83 in 1993-1999; HR, 0.48; 95% CI, 0.38-0.60 in 2000-2006; and HR, 0.44; 95% CI, 0.32-0.59 in 2007-2013) and 6.0 (HR, 0.72; 95% CI, 0.57-0.90; HR, 0.44; 95% CI, 0.33-0.60; and HR, 0.30; 0.20-0.46). In later diagnosis epochs, a greater number of patients with POMS were treated with DMTs, especially high-potency drugs, that were given earlier and for a longer period. Demographic characteristics and clinical disease activity at onset did not change significantly over time. CONCLUSIONS AND RELEVANCE: In POMS, the risk of persistent disability has been reduced by 50% to 70% in recent diagnosis epochs, probably owing to improvement in therapeutic and managing standards.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Baroncini D, Simone M, Iaffaldano P, et al. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurol. 2021. PMID: 33938921. doi:10.1001/jamaneurol.2021.1008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。